<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800317</url>
  </required_header>
  <id_info>
    <org_study_id>2015-8023</org_study_id>
    <nct_id>NCT02800317</nct_id>
    <nct_alias>NCT02792101</nct_alias>
  </id_info>
  <brief_title>RISAS Procedure in Node Positive Breast Cancer Following NAC</brief_title>
  <official_title>Primary Radioactive Iodine Seed Localisation in the Axilla in Axillary Node Positive Breast Cancer Combined With Sentinel Node Procedure (RISAS) Following Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy in clinically node positive breast cancer patients is increasingly administrated
      in a neoadjuvant setting. The standard treatment regimen in these cases is then: neoadjuvant
      chemotherapy (NAC) followed by breast surgery and an axillary lymph node dissection (ALND).
      NAC results in axillary pathologic complete response (pCR) in 1 out of 3 patients, indicating
      a complete absence of axillary metastases after completion of NAC. In such events, ALND can
      be regarded as overtreatment that creates unnecessary morbidity. Less invasive axillary
      surgery which can accurately assess axillary pCR is therefore preferred over standard ALND in
      all patients. In case of detection of remaining axillary lymph node metastases by this less
      invasive axillary surgical procedure, completion axillary treatment is standard of care.

      The novel RISAS procedure is introduced as a possible less invasive axillary staging
      procedure. RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in
      axillary node positive breast cancer combined with a Sentinel node procedure. The iodine seed
      in the axillary lymph node metastasis will be placed prior to start of NAC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification rate and accuracy (sensitivity, negative predictive value (NPV) and false negative rate (FNR)) of RISAS-procedure for identifying axillary pCR, with 95% confidence intervals will be calculated.</measure>
    <time_frame>Participants will be followed from the moment of first out-hospital clinic visit untill final breast surgery, an expected average of 4 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The identification rate and accuracy (sensitivity, NPV and FNR) of both techniques used in RISAS-procedure (i.e. SLNB and MARI) for identifying axillary pCR, will be calculated separately as well.</measure>
    <time_frame>Participants will be followed from the moment of first out-hospital clinic visit untill final breast surgery, an expected average of 4 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasm</condition>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Axillary Lymph Nodes</condition>
  <condition>Pathological Complete Response</condition>
  <arm_group>
    <arm_group_label>RISAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RISAS</intervention_name>
    <description>RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.</description>
    <arm_group_label>RISAS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient with pathologically confirmed axillary lymph node positive invasive
             primary breast cancer, treated with neoadjuvant chemotherapy

          -  Willing and able to undergo all study procedures.

          -  Has personally provided written informed consent.

        Exclusion Criteria:

          -  Age &lt; 18

          -  Pregnancy or lactation

          -  Contra indications for undergoing iodine seed placement or sentinel lymph node biopsy,
             such as allergic reaction on iodine, 99m Technetium or patent blue.

          -  Recurrent breast cancer

          -  Previous axillary surgery or radiotherapy

          -  Patients with periclavicular lymph node metastases (cN3)

          -  Patients with advanced breast cancer (i.e. patients with distant metastases, treated
             without any furter surgical procedures)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linetta B Koppert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janine M Simons, MD</last_name>
    <email>J.m.simons@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thiemo JA van Nijnatten, MD</last_name>
    <email>Thiemo.nijnatten@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine M Simons</last_name>
    </contact>
    <investigator>
      <last_name>Ernest JT Luiten, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine M Simons</last_name>
    </contact>
    <investigator>
      <last_name>Marjolein L Smidt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine M Simons</last_name>
    </contact>
    <investigator>
      <last_name>Linetta B Koppert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine M Simons</last_name>
    </contact>
    <investigator>
      <last_name>Carmen C van der Pol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>L.B. Koppert</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

